Intarcia Axes 60, Halts Studies after FDA Clinical Hold

Intarcia Therapeutics has eliminated approximately 60 of its 300 positions--about 20% of its workforce—and terminated two Phase III trials assessing a diabetes drug/device combination following an FDA clinical hold.Intarcia CEO Kurt Graves disclosed the job cuts to the Boston Business Journal , but added that the company was also looking to hire enough new staffers to keep its workforce at the same approximately 300 people it had before the layoffs.Graves said most of the positions it elim